Drug intelligence / Profile preview

cholecalciferol + calcium carbonate (AstraZeneca)

Development stage: Unknown
Lead developer: Astra Care Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Calory D3 is a branded generic combination of calcium and vitamin D3 (cholecalciferol) marketed by Astra Care Pharmaceuticals. It is primarily used as a nutritional supplement to treat or prevent calcium and vitamin D deficiencies, which are essential for maintaining bone health and preventing conditions such as osteoporosis, osteomalacia, and rickets. Vitamin D3 facilitates the intestinal absorption of calcium by acting as an agonist at the Vitamin D receptor, while calcium provides the structural component for bone mineralization.

Brand names: Calory D3
Other names: calcium + cholecalciferolcalcium + vitamin D3

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on cholecalciferol + calcium carbonate (AstraZeneca).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cholecalciferol + calcium carbonate (AstraZeneca).

Explore the full profile